Shawn Kavoussi MD

09/04/2026

Fusion of surgical and medical retina in the Susvimo intra-vitreal implant: grateful to the hardworking teams at Victoria Surgery Center and Roche / Genentech (especially Andy Lackey) for supporting our first case and bringing a new treatment opportunity for our patients. In the Phase 3 Archway trial, Susvimo with continuous release ranibizumab refilled every 6 months met its primary endpoint of non-inferior visual acuity compared to monthly ranibizumab injections, offering select nAMD patients a refillable option that can reduce treatment burden without compromising visual outcomes. This was an ideal option for our patient who not only lives in a rural area, but also has a small eye / short axial length and therefore experienced intra-ocular pressure spikes and transient optic nerve non-perfusion with each prior 0.05cc traditional intra-vitreal injection.

03/02/2026

Incredibly proud of the clinical trial team at Texas Retina Center for enrolling the FIRST patient in the landmark COMO Phase 3 study for diabetic macular edema sponsored by EyePoint.

This accomplishment is a testament to the hard work of our dedicated research coordinators Sethmini Rajaguru & Kourtney Storey from accelerated study start-up to first randomization this week. Special thanks to Ramiro Ribeiro, MD, PhD, Alejandro G Sabino Fernandez M.D and Jay S. Duker, M.D. at EyePoint for pushing the boundaries of innovation to potentially offer better treatments for our patients. Also special thanks to David Eichenbaum who has been a mentor every step of the way as we built a clinical research program at Texas Retina Center.

COMO (EYP-1901-303) evaluates Vorolanib, a novel tyrosine kinase inhibitor (TKI) intra-vitreal insert that blocks pro-angiogenic signaling from all VEGF isoforms and PDGFR, and also inhibits inflammatory IL-6 signaling by targeting JAK-1. Combining potent VEGF suppression with anti-inflammatory IL-6 inhibition can potentially offer more effective and longer-lasting results for our patients with sight-threatening diabetic macular edema.

08/18/2025

One third of diabetic eyes screened with undilated fundus photos in the P*P setting on a national telemedicine platform had evidence of pathology, including all levels of diabetic retinopathy from mild to proliferative; as well as macular edema, glaucoma, retinal vein occlusion, and vitreo-macular interface abnormalities. Potentially life-threatening pathology, including optic nerve edema, hollenhorst plaques, and choroidal neoplasms could also be seen in select cases. I had the pleasure of sharing this data recently at the 2025 American Society of Retina Specialists (ASRS) national meeting in Long Beach, CA.  Much credit to the team at Intelligent Retinal Imaging Systems for building an effective platform. 

08/01/2025

🎉 Congratulations to Dr. Shawn Kavoussi on publishing research using infrared video imaging to detect and measure eye floaters! Your work highlights how this dynamic technique improves visualization, enhances patient comfort, and supports clinical decision-making. The study also introduces the Macular Vitreous Opacity Score to help standardize documentation, guide treatment decisions, and assess outcomes from interventions. We are honored that your research utilized Heidelberg Engineering SPECTRALIS multimodal imaging platform.

📖 Read the abstract here: https://journals.sagepub.com/doi/10.1177/24741264241310219

05/20/2025

Yesterday my practice and 4D Molecular Therapeutics hosted a recruitment dinner for the pivotal phase 3 4FRONT-1 clinical trial evaluating intravitreal gene therapy for patients with wet age-related macular degeneration. Special thanks to Naghmeh Khayyat PhD and 4DMT for helping organize this opportunity for the Houston-area eye care community together and learn about the next generation of retina treatments.

12/16/2024

04/02/2024

How to protect your eyes and test your solar filters at home. Keep your retinas safe during the next solar eclipse on April 8. 🚨

10/05/2023

This beautiful IR + OCT image provided by Dr. Shawn Kavoussi shows a retinal detachment involving the macula, as the fovea has been spared.